

BIOMARIN PHARMACEUTICAL INC  
Form 4  
October 17, 2016

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
BIENAIME JEAN JACQUES

2. Issuer Name and Ticker or Trading Symbol  
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
08/03/2016

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Executive Officer

C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

SAN RAFAEL, CA 94901

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code |   |        |       | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|---------------------|---|--------|-------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                | V | Amount | Price |   |   |  |                                   |
| Common Stock                    | 08/03/2016 <sup>(1)</sup>            | 08/03/2016   | G                   | V | 400    | D     | \$ 0  | 378,184   | D  |                                   |
| Common Stock                    | 08/04/2016 <sup>(2)</sup>            | 08/04/2016   | G                   | V | 500    | D     | \$ 0  | 377,684   | D  |                                   |
| Common Stock                    | 08/24/2016 <sup>(3)</sup>            | 08/24/2016   | G                   | V | 200    | D     | \$ 0  | 377,484   | D  |                                   |
| Common Stock                    | 10/13/2016 <sup>(4)</sup>            | 10/13/2016   | M                   |   | 53,125 | A     | \$ 38.59  | 376,493 <sup>(5)</sup>  | D  |                                   |
|                                 | 10/13/2016 <sup>(4)</sup>            | 10/13/2016   | S                   |   | 53,125 | D     |   | 323,368 <sup>(5)</sup>  | D  |                                   |

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

|              |                           |            |   |        |   |            |         |   |                                      |
|--------------|---------------------------|------------|---|--------|---|------------|---------|---|--------------------------------------|
| Common Stock |                           |            |   |        |   | \$ 86.9753 |         |   |                                      |
|              |                           |            |   |        |   | <u>(6)</u> |         |   |                                      |
| Common Stock | 10/14/2016 <sup>(4)</sup> | 10/14/2016 | M | 11,000 | A | \$ 17.86   | 334,368 | D |                                      |
| Common Stock | 10/14/2016 <sup>(4)</sup> | 10/14/2016 | S | 11,000 | D | \$ 86.8922 | 323,368 | D |                                      |
|              |                           |            |   |        |   | <u>(7)</u> |         |   |                                      |
| Common Stock |                           |            |   |        |   |            | 25,758  | I | Shares held by Bienaime Family Trust |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----------------|---|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date | Title   |                            |
| Stock Option (right to buy Common Stock)   | \$ 38.59   | 10/13/2016 <sup>(4)</sup>            | 10/13/2016   | M                              | 53,125  | 11/22/2008   | 05/21/2018      | Common Stock  | 53,125                     |
| Stock Option (right to buy Common Stock)   | \$ 17.86   | 10/14/2016 <sup>(4)</sup>            | 10/14/2016   | M                              | 11,000  | 06/17/2009   | 12/16/2018      | Common Stock  | 11,000                     |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                         |       |
|--|---------------|-----------|-------------------------|-------|
|  | Director      | 10% Owner | Officer                 | Other |
| BIENAIME JEAN JACQUES<br>C/O BIOMARIN PHARMACEUTICAL INC.<br>770 LINDARO ST.<br>SAN RAFAEL, CA 94901 | X             |           | Chief Executive Officer |       |

## Signatures

|   |            |
|---|------------|
| /s/ Laura Randall Woodhead,<br>Attorney-in-Fact | 10/17/2016 |
| **Signature of Reporting Person                 | Date       |

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) On August 3, 2016, the reporting person gifted 400 shares to an educational institution.
- (2) On August 4, 2016, the reporting person gifted 500 shares to an educational institution.
- (3) On August 24, 2016, the reporting person gifted 200 shares to an educational institution.

(4) Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime.

(5) The number of shares reflects transfers made by Mr. Bienaime to his former spouse prior to October 13, 2016, of a total of 54,116 shares pursuant to a marital separation agreement.

(6) The price in column 4 is the weighted average price. The price actually received ranged from \$86.15 to \$88.23. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

(7) The price in column 4 is the weighted average price. The price actually received ranged from \$86.41 to \$87.78. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

(8) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.